Month: April 2024

Originally published on Essity Newscenter

Hygiene and health company Essity continues its purpose to break barriers to well-being by joining the Unstereotype Alliance, a thought and action platform convened by UN Women, with the mission to eradicate harmful stereotypes in media and advertising content.

The Unstereotype Alliance seeks to eradicate harmful stereotypes from advertising and media to help create a more equal world. Convened by UN Women, an organization within the United Nations dedicated to gender equality and the empowerment of women, the Alliance collectively acts to empower people in all their diversity by using advertising as a force for good to drive positive change all over the world.

Essity and its brands have a long history of breaking taboos, raise awareness against bias and act for equality. For example through campaigns by its feminine care brands Bodyform/Libresse/Nosotras/Saba, and the global market leading incontinence care brand TENA, such as “Blood Normal” which was the first TV advertisement for period products to replace blue liquid with a more representative red, “Viva La Vulva” and “Befriend your Body” which helps normalize the conversation about the female body and “The Last Lonely Menopause” which encourages conversations about menopause.

“Essity has presence in 150 countries, and we take great responsibility in building our brands with our consumers and customers in a responsible and inclusive way. By joining the Unstereotype Alliance we want to contribute to accelerating progress and look forward to collaborating with UN Women and peers worldwide to empower people in this endeavor”, says Tuomas Yrjölä, President Global Brand, Innovation & Sustainability at Essity.

Essity has been a partner to the United Nations Foundation since 2016 with the aim of contributing to the achievement of the Sustainable Development Goals (SDGs), with Goal 5: Gender Equality being one of Essity’s prioritized SDGs. 

For information about the Unstereotype Alliance, go to: http://www.unstereotypealliance.org

STEINHAUSEN, Switzerland, April 19, 2024 /3BL/ – Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has donated more than 7 million doses of medicine to its long-standing partner Direct Relief to support humanitarian medical relief efforts across the world. The donation came via Viatris’ Swiss affiliate, Viatris Pharma GmbH, and included medicine from a wide range of therapeutic areas, such as gastroenterology and cardiology, among others, to help meet urgent medical needs.

“Viatris is proud to support organizations that work to ensure people have access to healthcare, especially during times of crisis,” said Lara Ramsburg, Viatris’ Chief Corporate Affairs Officer. “The World Health Organization estimates more than 2 billion people globally do not have access to medicines, a situation much exacerbated by emergencies. The urgent health challenges and the growing areas of need are why we value partners like Direct Relief who are dedicated to providing resources for patients when and where they need care.”

Direct Relief is a humanitarian aid organization that works globally to expand access to medicine and healthcare by equipping doctors and nurses with lifesaving medical resources. The organization responds to crises of all types and humanitarian crises around the world.

“Guided by our mission to empower people worldwide to live healthier at every stage of life, we are grateful to work with Direct Relief to make the most impactful contributions possible,” says Lewis Pearson, Viatris’ Country Manager in Switzerland.

To learn more about Viatris’ commitment to sustainability and how the company is working with partners around the world to address some of the world’s most pressing health, environmental and social issues, please visit the Company’s 2022 Sustainability Report.

About Viatris

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life’s moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).